Pannash
  • About
    • Mission
    • Objectives
    • Editors
  • Non-ALCOHOLIC STEATOHEPATITIS (NASH)
    • Definitions
    • Epidemiology
    • Comorbidities
    • Pathophysiology
    • Diagnosis
    • Management
  • PPAR agonists
    • Science
    • pan-PPAR agonists
  • Resources
    • Commented Articles
    • Videos
    • Slides
    • Webinars
  • Newsroom
My Account

Category: Expert Perspective

This is our archive page
post-thumb

HCC in Patients with NAFLD/NASH

22 September 2021, by Prof. Bugianesi
post-thumb

NAFLD prevalence in Type 1 diabetes patients

22 September 2021, by G. Bozet, MD
post-thumb

Fatty liver index and risk of hypertension

22 September 2021, by D. Beard
post-thumb

Emerging drugs targeting specific points in NASH pathogenesis

20 September 2021, by G. Bozet, MD
post-thumb

Review: NAFLD, driver of chronic kidney disease

20 September 2021, by D. Beard
post-thumb

Children with suspected NAFLD: negative for other causes of liver disease

15 September 2021, by G. Bozet, MD
post-thumb

The Significance of the Mediterranean Diet in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review

15 September 2021, by D. Beard
post-thumb

Treatment of 3 major risk factors and fibrosis stage regression

13 September 2021, by G. Bozet, MD
post-thumb

Japan: NAFLD may affect half of the population by 2040

13 September 2021, by D. Beard
post-thumb

Dynamic changes in liver macrophage subsets during NASH

9 September 2021, by G. Bozet, MD

Posts navigation

1 2 … 26 Next page
This website is supported by

2021 Copyright, Pannash. Powered by Beyond | Terms & Conditions | Privacy Notice

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.Cookie Notice, Privacy Notice, Terms & Conditions
SettingsAcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Pannash
  • About
    • Mission
    • Objectives
    • Editors
  • Non-ALCOHOLIC STEATOHEPATITIS (NASH)
    • Definitions
    • Epidemiology
    • Comorbidities
    • Pathophysiology
    • Diagnosis
    • Management
  • PPAR agonists
    • Science
    • pan-PPAR agonists
  • Resources
    • Commented Articles
    • Slides
    • Video
  • Newsroom
  • My Account